Sartorius Stedim Biotech (SSB) and Repligen Corp., a global life sciences company focused on bioprocessing technologies, have entered into a collaboration to integrate Repligen’s XCell ATF cell retention control technology into SSB’s BIOSTAT STR large-scale single-use bioreactors to create novel perfusion-enabled bioreactors. The collaboration will result in a single control system for 50 L to 2,000 L bioreactors for use in perfusion cell culture applications. This single interface is designed to control cell growth, fluid management and cell retention in continuous and intensified bioprocessing and to simplify development and cGMP manufacture of biologics.
 
Sartorius and Repligen will further collaborate to equip SSB’s recently launched ambr 250ht perfusion single-use mini bioreactor system with Repligen’s KrosFlo hollow fiber filter technology. The bioreactor system will be sold by SSB as a complete single-use assembly. This design conserves hollow fiber filter technology across scales to help fast track development and scale up cell culture perfusion processes.
 
“Sartorius Stedim Biotech has continuously expanded its integrated upstream portfolio over the past years with a focus on robust and scalable, automated single-use solutions, optimized for high-cell-density applications. The collaboration with Repligen will result in easy-to-implement, high-performance and perfusion-ready bioreactors ranging from process development to commercial manufacturing scale,” said Stefan Schlack, head of marketing at SSB.

Christine Gebski, vice president of product management at Repligen, said, “We are excited to partner with Sartorius Stedim Biotech, a global innovator in bioreactor technology. The integration of our market-leading XCell™ ATF control technology with SSB’s high-performance bioreactors offers a simplified perfusion-enabled bioreactor solution for end users to develop cell culture processes more quickly and implement perfusion more efficiently.”